NASDAQ:CGENCompugen Stock Price, Forecast & News

Compugen's stock was trading at $11.83 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CGEN shares have increased by 21.0% and is now trading at $14.31. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Compugen.

Compugen is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Compugen.

Compugen Ltd. (NASDAQ:CGEN) released its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). During the same period in the prior year, the firm earned ($0.14) earnings per share. View Compugen's earnings history.

6 brokerages have issued twelve-month price targets for Compugen's stock. Their forecasts range from $13.00 to $28.00. On average, they anticipate Compugen's stock price to reach $18.67 in the next year. This suggests a possible upside of 30.4% from the stock's current price. View analysts' price targets for Compugen.

News stories about CGEN stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Compugen earned a coverage optimism score of -2.7 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutCompugen.

Some companies that are related to Compugen include Momenta Pharmaceuticals (MNTA), Ablynx (ABLYF), bluebird bio (BLUE), Halozyme Therapeutics (HALO), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Novavax (NVAX), Alector (ALEC), Bill.com (RVMD), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), Cortexyme (CRTX) and Regenxbio (RGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), NVIDIA (NVDA), Gilead Sciences (GILD), Novavax (NVAX), Pluristem Therapeutics (PSTI), Inovio Pharmaceuticals (INO), Pfizer (PFE), Sorrento Therapeutics (SRNE) and Alibaba Group (BABA).

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Compugen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Nikko Asset Management Americas Inc. (12.22%), Nikko Asset Management Americas Inc. (12.22%), RA Capital Management L.P. (4.32%), Morgan Stanley (1.27%), Taylor Frigon Capital Management LLC (0.92%) and DAFNA Capital Management LLC (0.88%).

CGEN stock was sold by a variety of institutional investors in the last quarter, including Taylor Frigon Capital Management LLC, Taylor Frigon Capital Management LLC, Morgan Stanley, Jane Street Group LLC, UBS Group AG, BlackRock Inc., Private Advisor Group LLC, and Citigroup Inc..

CGEN stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., DAFNA Capital Management LLC, Sofinnova Investments Inc., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Phoenix Holdings Ltd., Mackenzie Financial Corp, and Advisor Group Holdings Inc..

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CGEN stock can currently be purchased for approximately $14.31.

Compugen has a market capitalization of $979.09 million and generates $17.80 million in revenue each year. The biotechnology company earns $-27,340,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. Compugen employs 89 workers across the globe.

The official website for Compugen is www.cgen.com.

Compugen's mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]